Pan-RAF inhibitor exarafenib targets BRAF class II/III NSCLC and reveals ARAF-KSR1 resistance and combination strategies.
泛 RAF 抑制剂艾沙非尼靶向 BRAF II/III 类非小细胞肺癌,揭示 ARAF-KSR1 耐药性和联合治疗策略。
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-026-69216-3
Manabe Tadashi, Bergo Hannah C, Li Qingtian, Wang Tim Sen, Severson Paul, Miller Nichol, Lee Catherine, Yay Donderici Elifnur, Zhang Nicole, Wu Wei, Chou Yu-Ting, Kerr Daniel L, Allegakoen Paul, Grandinetti Kathryn B, Soroceanu Liliana, Pelham Robert J, Martin Eric S, Murphy Eric A, Khanna Vishesh, Neal Joel W, Chen Christopher T, Kato Shumei, Williams Richard, Bivona Trever G